June 2026
M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

Ney Carter Borges: Does APOC3 Inhibition Translates into Structural Coronary Plaque Modification

Ney Carter Borges/LinkedIn

Apr 5, 2026, 15:46

Ney Carter Borges: Does APOC3 Inhibition Translates into Structural Coronary Plaque Modification

Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:

“APOC3 Inhibition with Olezarsen and Coronary Atherosclerosis

The Essence – TIMI 73b imaging substudy evaluated whether intensive triglyceride-rich lipoprotein reduction with olezarsen translates into structural coronary plaque modification.

In this randomized, placebo – controlled trial, 468 patients with moderate hypertriglyceridemia and established or high cardiovascular risk underwent serial coronary CT angiography over 12 months.

Olezarsen produced profound lipid changes, including a 63.9% reduction in triglycerides, 71.9% reduction in remnant cholesterol, and a 16% decrease in apolipoprotein B (apoB), without affecting LDL cholesterol.

Despite these robust metabolic effects, the primary endpoint – percent change in noncalcified plaque volume (NCPV) – was not significantly different compared with placebo (Δ +2.98%; 95% CI −3.4 to 9.3; p equals 0.36).

Similarly, no meaningful differences were observed across secondary plaque components, including low-attenuation and total plaque volumes.

These findings highlight a critical mechanistic insight:

Substantial triglyceride and remnant cholesterol reduction alone may be insufficient to induce measurable short – term plaque regression, particularly when apoB lowering is modest.

Given that apoB reflects the total burden of atherogenic particles, the results reinforce its central role in atherosclerosis progression.

Longer – term outcome trials are required to determine whether APOC3 inhibition confers clinical cardiovascular benefit despite neutral imaging findings.”

Ney Carter Borges